BR112021019055A2 - Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios - Google Patents

Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios

Info

Publication number
BR112021019055A2
BR112021019055A2 BR112021019055A BR112021019055A BR112021019055A2 BR 112021019055 A2 BR112021019055 A2 BR 112021019055A2 BR 112021019055 A BR112021019055 A BR 112021019055A BR 112021019055 A BR112021019055 A BR 112021019055A BR 112021019055 A2 BR112021019055 A2 BR 112021019055A2
Authority
BR
Brazil
Prior art keywords
compounds
treatment
pharmaceutical compositions
inflammatory disorders
methods
Prior art date
Application number
BR112021019055A
Other languages
English (en)
Portuguese (pt)
Inventor
Denana Vrban
Marie Jary Helène
Marijana Komac
Mislav Orsulic
Oscar Mammoliti
Christophe Xavier Brys Reginald
Rhalid Akkari
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112021019055A2 publication Critical patent/BR112021019055A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112021019055A 2019-03-29 2020-03-24 Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios BR112021019055A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058064 WO2020200900A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
BR112021019055A2 true BR112021019055A2 (pt) 2021-11-30

Family

ID=66442982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019055A BR112021019055A2 (pt) 2019-03-29 2020-03-24 Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios

Country Status (18)

Country Link
US (1) US20220218679A1 (https=)
EP (1) EP3947378B1 (https=)
JP (1) JP2022526364A (https=)
KR (1) KR20210145238A (https=)
CN (1) CN113646305A (https=)
AR (1) AR118521A1 (https=)
AU (1) AU2020252038A1 (https=)
BR (1) BR112021019055A2 (https=)
CA (1) CA3134736A1 (https=)
CO (1) CO2021014223A2 (https=)
GB (1) GB201904373D0 (https=)
IL (1) IL286677A (https=)
MA (1) MA55497A (https=)
MX (1) MX2021011576A (https=)
PH (1) PH12021552375A1 (https=)
SG (1) SG11202110644WA (https=)
TW (1) TW202102501A (https=)
WO (1) WO2020200900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法
EP4434981A4 (en) * 2021-12-23 2025-08-20 Hangzhou Polymed Biopharmaceuticals Inc FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE
WO2024133560A1 (en) * 2022-12-21 2024-06-27 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
CN119751445B (zh) * 2024-12-10 2025-11-25 江南大学 6-乙炔基吡唑并[1,5-a]吡啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657242A4 (en) * 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine
JPWO2005108399A1 (ja) * 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP2018524372A (ja) * 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN109890829B (zh) * 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP3947378B1 (en) 2024-11-13
MX2021011576A (es) 2021-10-13
CN113646305A (zh) 2021-11-12
SG11202110644WA (en) 2021-10-28
TW202102501A (zh) 2021-01-16
CO2021014223A2 (es) 2021-11-19
CA3134736A1 (en) 2020-10-08
IL286677A (en) 2021-10-31
MA55497A (fr) 2022-02-09
WO2020200900A1 (en) 2020-10-08
JP2022526364A (ja) 2022-05-24
GB201904373D0 (en) 2019-05-15
EP3947378A1 (en) 2022-02-09
US20220218679A1 (en) 2022-07-14
AR118521A1 (es) 2021-10-20
PH12021552375A1 (en) 2022-09-19
AU2020252038A1 (en) 2021-11-25
KR20210145238A (ko) 2021-12-01

Similar Documents

Publication Publication Date Title
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112021019099A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
JOP20210154B1 (ar) مثبطات kif18a
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112015020998A2 (pt) compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EA202091512A1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
BR112018067312A2 (pt) compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose
BR112016012734A8 (pt) composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
BR112017006713A2 (pt) inibidor de egfr, e preparação e aplicação do mesmo
BR112022012684A2 (pt) Compostos cíclicos e métodos de uso dos mesmos
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA201790070A1 (ru) Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70
BR112012028674A2 (pt) inibidores de quinase bicíclica fundida
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201891710A1 (ru) Терапевтические соединения
MX383520B (es) Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
BR112021019110A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
MY197561A (en) Composition for increasing expression of pgc-1?
BR112022001002A2 (pt) Solvato de dmf, forma a, forma c, processos para a preparação do solvato de dmf, para a preparação da forma a de relugolix anidra, para a preparação da forma b de relugolix anidra e para a preparação da forma c de relugolix anidra, composição farmacêutica, e, método de tratamento de doença

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.